TY - JOUR
T1 - DNA damage response mediators MDC1 and 53BP1
T2 - constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours
AU - Bartkova, J
AU - Horejsí, Z
AU - Sehested, M
AU - Nesland, J M
AU - Rajpert-De Meyts, E
AU - Skakkebaek, N E
AU - Stucki, M
AU - Jackson, S
AU - Lukas, J
AU - Bartek, J
PY - 2007/11/22
Y1 - 2007/11/22
N2 - MDC1 and 53BP1 are critical components of the DNA damage response (DDR) machinery that protects genome integrity and guards against cancer, yet the tissue expression patterns and involvement of these two DDR adaptors/mediators in human tumours remain largely unknown. Here we optimized immunohistochemical analyses of human 53BP1 and MDC1 proteins in situ and identified their virtually ubiquitous expression, both in proliferating and quiescent, differentiated tissues. Focus formation by 53BP1 and/or MDC1 in human spermatogenesis and subsets of breast and lung carcinomas indicated physiological and 'pathological' activation of the DDR, respectively. Furthermore, aberrant reduction or lack of either protein in significant proportions of carcinomas supported the candidacy of 53BP1 and MDC1 for tumour suppressors. Contrary to carcinomas, almost no activation or loss of MDC1 or 53BP1 were found among testicular germ-cell tumours (TGCTs), a tumour type with unique biology and exceptionally low incidence of p53 mutations. Such concomitant presence (in carcinomas) or absence (in TGCTs) of DDR activation and DDR aberrations supports the roles of MDC1 and 53BP1 within the ATM/ATR-regulated checkpoint network which, when activated, provides an early anti-cancer barrier the pressure of which selects for DDR defects such as p53 mutations or loss of 53BP1/MDC1 during cancer progression.
AB - MDC1 and 53BP1 are critical components of the DNA damage response (DDR) machinery that protects genome integrity and guards against cancer, yet the tissue expression patterns and involvement of these two DDR adaptors/mediators in human tumours remain largely unknown. Here we optimized immunohistochemical analyses of human 53BP1 and MDC1 proteins in situ and identified their virtually ubiquitous expression, both in proliferating and quiescent, differentiated tissues. Focus formation by 53BP1 and/or MDC1 in human spermatogenesis and subsets of breast and lung carcinomas indicated physiological and 'pathological' activation of the DDR, respectively. Furthermore, aberrant reduction or lack of either protein in significant proportions of carcinomas supported the candidacy of 53BP1 and MDC1 for tumour suppressors. Contrary to carcinomas, almost no activation or loss of MDC1 or 53BP1 were found among testicular germ-cell tumours (TGCTs), a tumour type with unique biology and exceptionally low incidence of p53 mutations. Such concomitant presence (in carcinomas) or absence (in TGCTs) of DDR activation and DDR aberrations supports the roles of MDC1 and 53BP1 within the ATM/ATR-regulated checkpoint network which, when activated, provides an early anti-cancer barrier the pressure of which selects for DDR defects such as p53 mutations or loss of 53BP1/MDC1 during cancer progression.
KW - Adaptor Proteins, Signal Transducing
KW - Animals
KW - Breast Neoplasms/genetics
KW - Cell Cycle Proteins
KW - Cell Line, Tumor
KW - DNA Damage
KW - DNA-Binding Proteins/biosynthesis
KW - Humans
KW - Immunohistochemistry
KW - Intracellular Signaling Peptides and Proteins/genetics
KW - Lung Neoplasms/genetics
KW - Male
KW - Mice
KW - Mice, Inbred BALB C
KW - Neoplasms, Germ Cell and Embryonal/genetics
KW - Nuclear Proteins/biosynthesis
KW - Testicular Neoplasms/genetics
KW - Trans-Activators/biosynthesis
KW - Tumor Suppressor p53-Binding Protein 1
U2 - 10.1038/sj.onc.1210553
DO - 10.1038/sj.onc.1210553
M3 - Journal article
C2 - 17546051
SN - 0950-9232
VL - 26
SP - 7414
EP - 7422
JO - Oncogene
JF - Oncogene
IS - 53
ER -